Telephone Delivery of BRCA Genetic Counseling

Video

This video explores a study that found telephone-based genetic counseling for women at risk of hereditary breast and ovarian cancers was noninferior to in-person counseling, with no significant adverse effects on long-term outcomes.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      A recent study found that use of telephone-based genetic counseling for women at risk of hereditary breast and ovarian cancers was noninferior to in-person counseling, with no significant adverse effects on long-term outcomes.

      In this video, lead study author Anita Y. Kinney, PhD, RN, of the University of New Mexico in Albuquerque, discusses the results of the study. Click here to read more.

      Recent Videos
      Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
      Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
      ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
      ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
      Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
      Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
      Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
      Exploring CDK4/6 Endocrine Therapy for Low-Grade Serous Ovarian Cancer
      The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
      Evaluating Frontline Treatment Options for Low-Grade Serous Ovarian Cancer
      Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
      Distinguishing Low-Grade Serous Ovarian Cancer From Other Ovarian Cancer Types
      Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
      Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
      Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
      Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
      Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
      Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
      Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
      Avutometinib/Defactinib May be a New SOC in Low-Grade Serous Ovarian Cancer
      Related Content
      Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.

      FDA Grants Accelerated Approval to Avutometinib/Defactinib in KRAS+ LGSOC

      Roman Fabbricatore
      May 8th 2025
      Article

      Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.

      Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

      Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

      Kathleen N. Moore, MD, MS
      March 17th 2025
      Podcast

      Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

      The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

      Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

      Roman Fabbricatore
      April 2nd 2025
      Article

      The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

      Target Folate Receptor Alpha in Ovarian Cancer?

      Target Folate Receptor Alpha in Ovarian Cancer?

      Dmitriy Zamarin, MD, PhD
      September 17th 2018
      Podcast

      Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

      Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

      Data Show Need for Specialized Expertise in Advanced Ovarian Cancer Surgery

      Russ Conroy
      March 19th 2025
      Article

      Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

      Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

      Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

      Ariana Pelosci
      March 18th 2025
      Article

      Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.